Dade International increases Spectral Diagnostics holding:
This article was originally published in Clinica
US diagnostics company Dade International will exercise its warrants to purchase additional shares in Canadian cardiac assay developer Spectral Diagnostics. This follows the US launch of Spectral's CK-MB/Myoglobin panel test earlier this year (see Clinica No 644, p 18). Dade will spend $2 million and increase its stake in Spectral to around 6%.
You may also be interested in...
With positive data from two Phase III trials, Incyte hopes to file an NDA this year for topical Jakafi in mild-to-moderate AD.
Emerging Company Profile: Axcella uses Generally Recognized As Safe (GRAS) amino acids to create drug candidates for hepatic encephalopathy, NASH and other diseases.
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.